BioPulse Comments on Volatility of Stock
SAN DIEGO, Feb. 13 /PRNewswire/ -- BioPulse International, Inc. (OTC Bulletin Board: BIOP; Frankfurt: BPZ) today announced that although the company's policy is to generally avoid commenting on its stock performance, given the unusual recent volatility and the numerous phone calls that ensued, BioPulse considers it appropriate.
Obviously, weak general market conditions are a contributing factor. But BioPulse's belief is that recent chat room posts and stories, which contain "fake" information or are mean spirited and manipulative, are the primary cause. Unfortunately in the Internet age, public companies both big and small have been subject to these unfortunate types of events. A public company's only recourse is to 1) continue to successfully execute its business plan; 2) communicate with its shareholders; 3) aggressively pursue legal, regulatory, and criminal channels.
BioPulse president Loran Swensen commented, "Although no company is without risk, we are proud of our accomplishments. BioPulse has made extraordinary progress recently in building a truly world class team (more names coming), successfully concluding two minor financings, preparing for an exchange listing upgrade, moving to a new 17,000 sq ft. headquarters in San Diego, retaining powerful Mintz Levin as counsel, maintaining our fourth consecutive quarterly profit on over 400% revenue growth, and most importantly, building a portfolio of proprietary cancer therapeutics and diagnostics that in some cases may ultimately have a profound impact on society, particularly our TK-1 Immmunoasssy. It is these very products, and a traditional FDA protocol model that BioPulse will communicate to our shareholders soon, which are potentially of great value and are the primary focus of the company's future. Our research and development clinic operations in Mexico (although quite profitable, growing in demand, and held in high esteem in its region and alternative communities) have been essentially the only subject of these mean spirited posts and stories. Although this is expected to be a very small part of BioPulse's future revenues, we would like to correct any falsehoods. 1) A chat room post stating that 450 patients have just died in the German clinic is obviously a 'fake' post and will be immediately investigated. 2) Recent posts and stories as to the clinic in Mexico not being licensed to perform its various clinical procedures, etc., is absolutely a falsehood."
Dr. Omar Sanchez, director of the BioPulse clinic in Mexico, commented, "We are delighted that our new laboratory has received its second full openly approved certification in general medicine and homeopathic/alternative treatments by Dr. Carlos Alberto Astorga Othon, from the Baja California Health Department - License #99020089 November 23, 2000. We appreciate our good standing relationship that we enjoy with the health department, and as a result, our clinic has some of the most modern diagnostics equipment available in northern Mexico." Dr. Sanchez also explained that his clinic has 56 employees that include 6 fully licensed medical doctors, including 1 oncologist, 2 surgeons, an endoscopist, and maintains a staff of 23 fully registered nurses.
About BioPulse:
This fast growing, profitable, San Diego based biotech company is combining alternative and biotech treatments for cancer and other diseases. The company owns a compelling portfolio of proprietary therapeutics and diagnostics that are the subject of trials at clinics outside the United States, which offer a comprehensive array of state-of-the-art procedures.
Various statements made within this press release may constitute "forward-looking statements" for purposes of the Securities and Exchange Commission's "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934. The forward-looking statements contained herein involve risks and uncertainties that could cause results to differ materially from the Company's expectations.
CONTACT: John Liviakis of Liviakis Financial Communications, Inc., 415-389-4670, or fax, 415-389-4694, Email: moreinfo@lfcnet.com, for BioPulse International, Inc.
SOURCE BioPulse International, Inc.
CO: BioPulse International, Inc.
ST: California
IN: BIO MTC
SU:
02/13/2001 05:00 EST prnewswire.com |
